

ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY

PROTOCOL UPDATE TO ALLIANCE A031803

**PHASE II TRIAL OF INTRAVESICAL GEMCITABINE AND MK-3475 (PEMBROLIZUMAB)
IN THE TREATMENT OF PATIENTS WITH BCG-UNRESPONSIVE NON-MUSCLE
INVASIVE BLADDER CANCER**

*NCI-supplied agent: MK-3475 (Pembrolizumab) (NSC # 776864, IND # [REDACTED]); IND holder: DCTD,
NCI Commercial agent: Gemcitabine hydrochloride (NSC # 613327)*

<input checked="" type="checkbox"/> Update:	<input type="checkbox"/> Status Change:
<input type="checkbox"/> Eligibility changes	<input type="checkbox"/> Activation
<input type="checkbox"/> Therapy / Dose Modifications / Study Calendar changes	<input type="checkbox"/> Closure
<input checked="" type="checkbox"/> Informed Consent changes	<input type="checkbox"/> Suspension / temporary closure
<input type="checkbox"/> Scientific / Statistical Considerations changes	<input type="checkbox"/> Reactivation
<input type="checkbox"/> Data Submission / Forms changes	
<input type="checkbox"/> Editorial / Administrative changes	
<input checked="" type="checkbox"/> Other: Updated pembrolizumab CAEPR and Condensed Risk Profile.	

The changes included in this update to A031803 have been made in response to the NCI Action Letter from Dr. Brian Ko (brian.ko@nih.gov). This Action Letter is posted on the A031803 study page on the CTSU website. Therefore, the model consent form has been revised to incorporate these new risks, consistent with the NCI Model Consent Template instructions. A revised CAEPR for pembrolizumab with new risks has been added to the protocol.

No recommended level of IRB review is provided by the Alliance as the CIRB is the IRB of record for this trial. This amendment must be implemented within 30 days after posting.

Reconsent is required for all patients on active pembrolizumab treatment and for those patients who have consented but have not yet started treatment. Please refer to the CIRB amendment application and guidelines for further instructions.

UPDATES TO THE PROTOCOL:

Section 9.4 (Comprehensive Adverse Events and Potential Risks List (CAEPR) for Pembrolizumab MK-3475, NSC 776864)

This section has been revised to include the updated pembrolizumab (MK-3475) CAEPR (Version 2.9, January 31, 2025) provided by CTEP. Changes from Version 2.8 to Version 2.9 include the following:

- Increase in Risk Attribution:
 - Changed to Likely from Less Likely: Anemia
 - Changed to Less Likely from Also Reported on Pembrolizumab (MK-3475) Trials But with Insufficient Evidence for Attribution: Constipation; Cough; Dyspnea
- Deleted Risk:
 - Also Reported on Pembrolizumab (MK-3475) Trials But With Insufficient Evidence for Attribution: Alopecia; Dry skin
- Modified Specific Protocol Exceptions to Expedited Reporting (SPEER) reporting requirements:
 - Deleted: Arthralgia; Diarrhea; Fatigue; Nausea; Pruritus; Rash maculo-papular

Section 13.10 Inclusion of Women and Minorities

The word “gender” has been changed to “sex” per the recent government Executive Order.

UPDATES TO THE MODEL CONSENT:

What risks can I expect from taking part in this study?

Based on the updated CAEPR described above, the following changes have been made to the NCI condensed risk profile for pembrolizumab (MK-3475) (found under “Possible Side Effects of Pembrolizumab”):

- Increase in Risk Attribution:
 - Changed to Common from Occasional: Anemia which may require blood transfusion
 - Changed to Occasional from Rare: Lung problems (pneumonitis and other conditions). Symptoms may include: new or worsening cough, chest pain, shortness of breath
 - Changed to Occasional from Also Reported on Pembrolizumab (MK-3475) Trials But With Insufficient Evidence for Attribution (i.e., added to the Risk Profile): Constipation; Cough
- Provided Further Clarification:
 - Skin: itching; acne; rash (can be severe); blisters and peeling on the skin, mouth; skin changes; hives (under Occasional) is now reported as Skin: itching; acne; rash (can be severe); blisters and peeling on the skin; skin changes; hives (under Occasional).
 - Damage to organs in the body when donor cells attack host organs which may cause yellowing of eyes and skin, itchy dry skin, diarrhea or muscle weakness (under Rare and Serious), should have been reported as Damage to organs in the body when donor cells attack host organs which may cause yellowing of eyes and skin, itchy dry skin (under Rare and Serious).

PLEASE NOTE: The potential risks listed in the CAEPR whose relationship to pembrolizumab is still undetermined are not required by CTEP to be described in the ICD; however, they may be communicated to patients according to local IRB requirements.

A replacement protocol and consent document have been issued.

ATTACH TO THE FRONT OF EVERY COPY OF THIS PROTOCOL

Research Study Informed Consent Document

Study Title for Participants: Testing the addition of an anti-cancer drug, Pembrolizumab, to the usual intravesical chemotherapy treatment (Gemcitabine) for the treatment of BCG-unresponsive Non-muscle invasive bladder cancer

Official Study Title for Internet Search on <http://www.ClinicalTrials.gov>: Protocol A031803, Phase II Trial of Intravesical Gemcitabine and MK-3475 (pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NCT04164082)

What am I being asked to do?

We are asking you to take part in a research study. This study has public funding from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) in the United States Department of Health and Human Services. We do research studies to try to answer questions about how to prevent, diagnose, and treat diseases like cancer.

We are asking you to take part in this research study because you have high risk non-muscle invasive bladder cancer which has not responded to initial treatment with Bacillus Calmette–Guerin (BCG).

Taking part in this study is your choice.

You can choose to take part or you can choose not to take part in this study. You also can change your mind at any time. Whatever choice you make, you will not lose access to your medical care or give up any legal rights or benefits.

This document has important information to help you make your choice. Take time to read it. Talk to your doctor, family, or friends about the risks and benefits of taking part in the study. It's important that you have as much information as you need and that all your questions are answered. See the “Where can I get more information?” section for resources for more clinical trials and general cancer information.

This study is conducted by the Alliance for Clinical Trials in Oncology, a national clinical research group supported by the National Cancer Institute. The Alliance is made up of cancer doctors, health professionals, and laboratory researchers, whose goal is to develop better treatments for cancer, to prevent cancer, to reduce side effects from cancer, and to improve the quality of life of cancer patients.

Why is this study being done?

This study is being done to answer the following question:

Can we lower the chance of your bladder cancer coming back by adding the drug MK-3475 (pembrolizumab) to an existing treatment option for bladder cancer?

We are doing this study because we want to find out if this approach is better or worse than the usual approach for your bladder cancer. The usual approach is defined as care most people get for bladder cancer.

What is the usual approach to my bladder cancer?

The usual approach for patients who are not in a study is bladder removal or additional intravesical therapy alone. Bladder removal is an effective treatment but results in potential negative impact to quality of life. Intravesical therapy alone is not very effective and your disease may spread during treatment. The usual approach does not include FDA-approved treatments.

What are my choices if I decide not to take part in this study?

- You may choose to have the usual approach described above.
- You may choose to take part in a different research study, if one is available.
- You may choose not to be treated for cancer.
- You may choose to only get comfort care to help relieve your symptoms and not get treated for your cancer.

What will happen if I decide to take part in this study?

If you decide to take part in this study, once a week for 6 weeks, you will get gemcitabine into the bladder through a small tube; this is called “intravesical” treatment. In addition, you will receive pembrolizumab every 3 weeks for 12 weeks. This 12-week period is called induction therapy. If the induction therapy is effective, about 6 weeks after induction therapy ends, you will start to receive intravesical gemcitabine and pembrolizumab through a vein in your arm every three weeks for 36 weeks.

After you finish your treatment, your doctor and study team will watch you for side effects. They will check you every 3 months for 2 years after treatment. After that, they will check you every 6 months for 3 years. This means you will keep seeing your doctor for 5 years after treatment.

What are the risks and benefits of taking part in this study?

There are both risks and benefits to taking part in this study. It is important for you to think carefully about these as you make your decision.

Risks

We want to make sure you know about a few key risks right now. We give you more information in the “What risks can I expect from taking part in this study?” section.

If you choose to take part in this study, there is a risk that MK-3475 (pembrolizumab) plus intravesical gemcitabine will not be as good as intravesical gemcitabine alone at preventing your cancer from coming back after treatment, or as good as bladder removal at preventing your cancer from coming back after treatment.

There is also a risk that you could have side effects from the MK-3475 (pembrolizumab) and intravesical gemcitabine. These side effects may be worse and may be different than you would get with the usual approach for your bladder cancer.

Some of the most common side effects that the study doctors know about are:

- Urinary frequency
- Urinary urgency
- Urinary retention
- Blood in the urine
- Bladder pain
- Fatigue

There may be some risks that the study doctors do not yet know about.

Benefits

There is some evidence in people with metastatic bladder cancer that adding MK-3475 (pembrolizumab) to the usual approach (intravesical gemcitabine) may delay the return of cancer for longer than the usual approach alone. It is unlikely that it will work in everyone with your cancer or help you live longer. This study may help the study doctors learn things that may help other people in the future.

If I decide to take part in this study, can I stop later?

Yes, you can decide to stop taking part in the study at any time.

If you decide to stop, let your study doctor know as soon as possible. It's important that you stop safely. This may mean slowly stopping the study drugs so that there is not a sudden unsafe change, risk to your health. It's important that your doctor is aware you stopped so other treatment options can be discussed. If you stop, you can decide if you want to keep letting the study doctor know how you are doing.

Your study doctor will tell you about new information or changes in the study that may affect your health or your willingness to continue in the study.

Are there other reasons why I might stop being in the study?

Yes. The study doctor may take you off the study if:

- Your health changes and the study is no longer in your best interest.
- New information becomes available and the study is no longer in your best interest.
- You do not follow the study rules.
- For women: You become pregnant while on the study.
- The study is stopped by the National Cancer Institute (NCI), Institutional Review Board (IRB), Food and Drug Administration (FDA). The study sponsor is the organization who oversees the study.

It is important that you understand the information in the informed consent before making your decision. Please read, or have someone read to you, the rest of this document. If there is anything you don't understand, be sure to ask your study doctor or nurse.

What is the purpose of this study?

The purpose of this study is to test the good and bad effects of the drug called MK-3475 (pembrolizumab) in combination with intravesical gemcitabine. MK-3475 (pembrolizumab) and intravesical gemcitabine could delay the return of your cancer, but it could also cause side effects, which are described in the risks section below. The study doctors hope to learn if the study drugs will improve the risk that the cancer will come back by about 30%.

MK-3475 (pembrolizumab) and intravesical gemcitabine have already been approved by the FDA to treat other cancers as well as different stages of bladder cancer. This drug combination has not been approved by the FDA for this type of cancer.

There will be about 163 people taking part in this study.

What are the study groups?

In this study, there are no study groups and all patients will receive the same therapy. You will get a standard therapy for your type of bladder cancer, which is intravesical gemcitabine. In addition, you will get the study drug MK-3475 (pembrolizumab).

Treatment schedule: Once a week for 6 weeks, you will get gemcitabine into the bladder through a small tube, this is called "intravesical" treatment. In addition, you will receive MK-3475 (pembrolizumab) every 3 weeks for 12 weeks. This 12-week period is called induction therapy. If the induction therapy is effective, about 6 weeks after induction therapy ends, you will start to receive intravesical gemcitabine and MK-3475 (pembrolizumab) through a vein in your arm for every three weeks for 36 weeks. This is called "maintenance" therapy. Each three-week period is called a "cycle." This study has 16 cycles in all.

You will not be able to get additional doses of the drug. This drug is not approved by the FDA for treatment of your disease.

What exams, tests, and procedures are involved in this study?

Before you begin the study, your doctor will review the results of your exams, tests, and procedures. This helps your doctor decide if it is safe for you to take part in the study. Before you join the study, you will not be allowed to take live vaccines. If you join the study, you will have more exams, tests, and procedures to closely monitor your safety and health. Most of these are included in the usual care you would get even if you were not in a study.

Some exams, tests, and procedures are a necessary part of the research study, but would not be included in usual care. Listed below are procedures that will be done for research purposes only.

Your study doctor will need to use some of the tissue left over from your biopsy when you were diagnosed with cancer as part of your usual care. This sample is a required part of the study. The tissue will be used to perform research to better understand how bladder cancer grows and can be more effectively treated. You and your study doctor will not get the results of this testing. If there is not enough tissue left over from your biopsy when you were diagnosed with cancer, your study doctor will not be required to do another biopsy to get this tissue for the purpose of this study.

What risks can I expect from taking part in this study?

General Risks

If you choose to take part in this study, there is a risk that Pembrolizumab (MK-3475) and intravesical gemcitabine may not be as good as bladder removal or intravesical gemcitabine alone at preventing your cancer from coming back.

You also may have the following discomforts:

- Spend more time in the hospital or doctor's office.
- Be asked sensitive or private questions about things you normally do not discuss.
- May not be able to take part in future studies.

The Pembrolizumab (MK-3475) and intravesical gemcitabine used in this study could be very harmful to an unborn or newborn baby. There may be some risks that doctors do not yet know about. It is very important that you check with your study doctor about what types of birth control or pregnancy prevention to use during the study and for 6 months after you have completed the study.

This study will use a sample of your tissue. Generally, your hospital will keep some of your tissue. This tissue may be used to help treat your cancer in the future. Because this study will need to use some of this tissue, there is a small risk that it could be used up.

Side Effect Risks

The drugs, Pembrolizumab (MK-3475) and intravesical gemcitabine, used in this study may affect how different parts of your body work such as your liver, kidneys, heart, and blood. The study doctor will test your blood and let you know if changes occur that may affect your health.

There is also a risk that you could have other side effects from the study cystoscopies.

Here are important things to know about side effects:

1. The study doctors do not know who will or will not have side effects.
2. Some side effects may go away soon, some may last a long time, and some may never go away.
3. Some side effects may make it hard for you to have children.
4. Some side effects may be mild. Other side effects may be very serious and even result in death.

You can ask your study doctor questions about side effects at any time. Here are important ways to make side effects less of a problem:

- If you notice or feel anything different, tell your study doctor. He or she can check to see if it is a side effect.
- Your study doctor will work with you to treat your side effects.
- Your study doctor may adjust the study drugs to try to reduce side effects.

This study is looking at a combination of the usual drugs used to treat this type of cancer. This different combination of drugs may increase your side effects or may cause new side effects.

Drug Risks

The tables below show the most common and most serious side effects doctors know about. Keep in mind that there might be other side effects doctors do not yet know about. If important new side effects are found, the study doctor will discuss these with you.

Table of Possible Side Effects for Pembrolizumab (MK-3475)
(CAEPR Version 2.9, January 31, 2025)

<p>COMMON, SOME MAY BE SERIOUS</p> <p>In 100 people receiving pembrolizumab (MK-3475), more than 20 and up to 100 may have:</p> <ul style="list-style-type: none"> • Tiredness <p>Pembrolizumab (MK-3475) may cause your immune system to attack normal organs and cause side effects in many parts of the body. These problems may include but are not limited to:</p> <ul style="list-style-type: none"> • Anemia which may require blood transfusion
<p>OCCASIONAL, SOME MAY BE SERIOUS</p> <p>In 100 people receiving pembrolizumab (MK-3475), from 4 to 20 may have:</p> <ul style="list-style-type: none"> • Constipation, nausea • Loss of appetite • Pain in back • Joint stiffness • Cough • Swelling and redness of the skin <p>Pembrolizumab (MK-3475) may cause your immune system to attack normal organs and cause side effects in many parts of the body. These problems may include but are not limited to:</p> <ul style="list-style-type: none"> • Pain in lymph nodes • Blood clot which may cause bleeding, confusion, paralysis, seizures and blindness • Hormone gland problems (especially the thyroid, pituitary and adrenal glands, and pancreas). Signs and symptoms may include: headaches that will not go away or unusual headaches, extreme tiredness or changes in mood or behavior decreased sex drive; weight loss or weight gain; excessive thirst or urine; dizziness or fainting • Intestinal problems (colitis) that can rarely lead to tears or holes in your intestine. Signs and symptoms of colitis may include: diarrhea or increase in bowel movements, blood in your stools or dark, tarry, sticky stools, severe belly pain or tenderness • Diarrhea • Sores in the mouth which may cause difficulty swallowing • Pain in belly • Sores in the bowels • Chills, fever • Reaction during or following a drug infusion which may cause fever, chills, rash, low blood pressure • Liver problems (hepatitis) which can cause liver failure. Signs and symptoms of hepatitis may include: yellowing of your skin or the whites of your eyes, severe nausea or vomiting; drowsiness; pain in the right upper belly • Lung problems (pneumonitis and other conditions). Symptoms may include: new or worsening cough, chest pain, shortness of breath

- Pain or swelling of the joints
- Problem of the muscle, including swelling, which can cause muscle pain and severe muscle weakness sometimes with dark urine
- Skin: itching; acne; rash (can be severe); blisters and peeling on the skin; skin changes; hives

RARE, AND SERIOUS

In 100 people receiving pembrolizumab (MK-3475), 3 or fewer may have:

- A syndrome starting with flu-like symptoms and followed by swelling, tenderness which may cause flu-like symptoms, blurred vision, ringing in the ears, changes in hair or hair loss
- Inability to digest food which may cause bloating
- Swelling of the gallbladder
- Swelling of the spinal cord
- Feeling of "pins and needles" in arms and legs
- Redness, pain or peeling of palms and soles

Pembrolizumab (MK-3475) may cause your immune system to attack normal organs and cause side effects in many parts of the body. These problems may include but are not limited to:

- Heart problems including swelling and heart failure. Symptoms and signs of heart problem may include: Shortness of breath, swelling of the ankle and body
- Swelling and redness of the eye which may cause blurred vision with a chance of blindness
- Swelling of the bowels
- Allergic reaction which may cause rash, low blood pressure, wheezing, shortness of breath, swelling of the face or throat
- Damage to organs in the body when donor cells attack host organs which may cause yellowing of eyes and skin, itchy dry skin
- Damage to organs in the body when the body produces too many white cells
- A condition with high blood sugar which leads to tiredness, frequent urination, excessive thirst, headache, nausea and vomiting, and can result in coma
- Problem of the nerves that can cause paralysis. Signs and symptoms may include: numbness, tingling of hands and feet; weakness of the arms, legs
- Swelling of the brain (encephalitis/meningitis) which may cause headache, confusion, sleepiness, seizures and stiff neck
- Kidney problems, including nephritis and kidney failure requiring dialysis. Signs of kidney problems may include: decrease in the amount of urine, blood in your urine, ankle swelling
- Skin rash developing 1-8 weeks after a drug is given which may be accompanied by fever, lymph node swelling and organ failure
- Swelling or tenderness of blood vessels

Pembrolizumab works by helping your immune system to fight your cancer. However, pembrolizumab can also cause your immune system to attack normal organs and tissues in your body and can affect the way they work, which can result in side effects. These side effects may be serious (i.e. causing hospitalization or be life threatening), may result in death, and/or may occur after you stop taking

pembrolizumab. These side effects can affect more than one of your normal organs and tissues at the same time.

Possible Side Effects of Gemcitabine (Table Version Date: October 17, 2019)

<p align="center">COMMON, SOME MAY BE SERIOUS</p>
<p align="center">In 100 people receiving Gemcitabine, more than 20 and up to 100 may have:</p>
<ul style="list-style-type: none"> • Infection, especially when white blood cell count is low • Bruising, bleeding • Anemia which may require a blood transfusion • Blood in urine • Nausea, vomiting • Flu-like symptoms of muscle pain, fever, headache, chills and fatigue • Muscle weakness • Feeling of "pins and needles" in arms and legs • Numbness and tingling of the arms and legs • Swelling of arms, legs • Tiredness • Difficulty sleeping • Rash • Hair loss

<p align="center">OCCASIONAL, SOME MAY BE SERIOUS</p>
<p align="center">In 100 people receiving Gemcitabine, from 4 to 20 may have:</p>
<ul style="list-style-type: none"> • Fluid in the organs which may cause low blood pressure, shortness of breath, swelling of ankles • Scarring of the lungs • Shortness of breath • Liver damage which may cause yellowing of eyes and skin, swelling • Diarrhea, constipation • Sores in mouth which may cause difficulty swallowing • Allergic reaction which may cause rash, low blood pressure, wheezing, shortness of breath, swelling of the face or throat • Swelling and redness of the area of radiation • Blisters on the skin

RARE, AND SERIOUS
In 100 people receiving Gemcitabine, 3 or fewer may have:
<ul style="list-style-type: none"> • Brain damage, Posterior Reversible Encephalopathy syndrome, which may cause headache, seizure, blindness • Blockage of the airway which may cause cough • Blood clot • Severe blood Infection • Anemia, kidney problems which may require dialysis

Rarely, there are problems getting enough supplies of the study drug. If that happens, your doctor will talk with you about your options.

What are my responsibilities in this study?

If you choose to take part in this study you will need to:

- Keep your study appointments.
- Tell your doctor about:
 - all medications and supplements you are taking
 - any side effects
 - any doctors' visits or hospital stays outside of this study
 - if you have been or are currently in another research study.

For women: Do not get pregnant or breastfeed while taking part in this study. **For men:** Do not father a baby while taking part in this study. **For all:** Tell your study doctor right away if you think that you or your partner have become pregnant during the study or within 6 months after your last dose of study drug.

What are the costs of taking part in this study?

You and/or your insurance plan will need to pay for the costs of medical care you get as part of the study, just as you would if you were getting the usual care for your bladder cancer except for MK-3475 (pembrolizumab). This includes:

- the costs of tests, exams, procedures, and drugs that you get during the study to monitor your safety, and prevent and treat side effects.
- the costs of getting the MK-3475 (pembrolizumab) ready and giving it to you.
- your insurance co-pays and deductibles.

Talk to your insurance provider and make sure that you understand what your insurance pays for and what it doesn't pay for if you take part in this clinical trial. Also, find out if you need approval from your plan before you can take part in the study.

Ask your doctor or nurse for help finding the right person to talk to if you are unsure which costs will be billed to you or your insurance provider.

You or your insurance provider will not have to pay for the MK-3475 (pembrolizumab) while you take part in this study.

You will not be paid for taking part in this study. The research may lead to new tests, drugs, or other products for sale. If it does, you will not get any payment.

What happens if I am injured because I took part in this study?

If you are injured as a result of taking part in this study and need medical treatment, please talk with your study doctor right away about your treatment options. The study sponsors will not pay for medical treatment for injury. Your insurance company may not be willing to pay for a study-related injury. Ask them if they will pay. If you do not have insurance, then you would need to pay for these medical costs.

If you feel this injury was caused by medical error on the part of the study doctors or others involved in the study, you have the legal right to seek payment, even though you are in a study. Agreeing to take part in this study does not mean you give up these rights.

Who will see my medical information?

Your privacy is very important to us. The study doctors will make every effort to protect it. The study doctors have a privacy permit to help protect your records if there is a court case.

However, some of your medical information may be given out if required by law. If this should happen, the study doctors will do their best to make sure that any information that goes out to others will not identify who you are.

Some of your health information, such as your response to cancer treatment, results of study tests, and medicines you took, will be kept by the study sponsor in a central research database. However, your name and contact information will not be put in the database. If information from this study is published or presented at scientific meetings, your name and other personal information will not be used.

There are organizations that may look at or receive copies of some of the information in your study records. Your health information in the research database also may be shared with these organizations. They must keep your information private, unless required by law to give it to another group.

Some of these organizations are:

- The study sponsor and any company supporting the study now or in the future. This would include any organization helping the company with the study.

- The NCI Central IRB, which is a group of people who review the research with the goal of protecting the people who take part in the study.
- The FDA and the groups it works with to review research.
- The NCI and the groups it works with to review research.
- The NCI's National Clinical Trials Network and the groups it works with to conduct research.

In addition to storing data in the study database, data from studies that are publicly funded may also be shared broadly for future research with protections for your privacy. The goal of this data sharing is to make more research possible that may improve people's health. Your study records may be stored and shared for future use in public databases. However, your name and other personal information will not be used.

Some types of future research may include looking at your information and information from other patients to see who had side effects across many studies or comparing new study data with older study data. However, right now we don't know what research may be done in the future using your information. This means that:

- You will not be asked if you agree to take part in the specific future research studies using your health information.
- You and your study doctor will not be told when or what type of research will be done.

Where can I get more information?

You may visit the NCI web site at <http://cancer.gov/> for more information about studies or general information about cancer. You may also call the NCI Cancer Information Service to get the same information at: 1-800-4-CANCER (1-800-422-6237).

A description of this clinical trial will be available on <http://www.ClinicalTrials.gov>, as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time.

You can talk to the study doctor about any questions or concerns you have about this study or to report side effects or injuries. Contact the study doctor _____ (*insert name of study doctor[s]*) at _____ (*insert telephone number*).

For questions about your rights while in this study, call the _____ (*insert name of organization or center*) Institutional Review Board at _____ (*insert telephone number*).

Optional studies that you can choose to take part in

This part of the consent form is about optional studies that you can choose to take part in. They are separate from the main study described above. These optional studies will not benefit your health. The researchers leading these optional studies hope the results will help other people

with cancer in the future. The results will not be added to your medical records and you or your study doctor will not know the results.

Taking part in these optional studies is your choice. You can still take part in the main study even if you say “no” to any or all of these studies. There is no penalty for saying “no.” You and your insurance company will not be billed for these optional studies. If you sign up for, but cannot complete any of these studies for any reason, you can still take part in the main study.

Circle your choice of “yes” or “no” for the following study.

Optional sample collections for known laboratory studies and/or storage for possible future studies

Researchers are trying to learn more about cancer and other health problems using blood and tissue samples from people who take part in clinical trials. By studying these samples, researchers hope to find new ways to prevent, detect, treat, or cure diseases.

Some of these studies may be about how genes affect health and disease. Other studies may look at how genes affect a person’s response to treatment. Genes carry information about traits that are found in you and your family. Examples of traits are the color of your eyes, having curly or straight hair, and certain health conditions that are passed down in families. Some of the studies may lead to new products, such as drugs or tests for diseases.

Known future studies

If you choose to take part in this optional study, researchers will collect blood, urine and bladder cancer tissue for research to evaluate the genetic and other possible biological cause of your bladder cancer and help us gain a better understanding of what leads to bladder cancer growth.

Unknown future studies

If you choose to take part in this optional study, any leftover blood, tissue and urine will be stored. Storing samples for future studies is called “biobanking.” The biobank is being run by the Alliance for Clinical Trials in Oncology and is supported by the NCI. Also, any health-related information, such as your response to cancer treatment, results of study tests, and medicines you took, will be stored for future use.

We don’t know what research may be done in the future using your leftover blood and tissue samples. This means that:

- You will not be asked if you agree to take part in the future research studies.
- You and your study doctor will not be told when or what type of research will be done.
- Future research studies may include sequencing of all or part of your DNA called genomic sequencing. All your genetic information makes up your genome. Genomic sequencing is a test that records all or part of the pieces of DNA that are in your genes,

piece by piece. This is usually done to look for changes in your genome that may cause health problems.

- You will not get reports or other information about any research that is done using your samples.

What is involved in this optional sample collection?

If you agree to take part, here is what will happen next:

1. About 4 teaspoons of blood will be collected from a vein in your arm before you start the treatment, on Day 1 of treatment cycle 1, 2 and 5, and if your disease gets worse. A sample from the tissue that was collected when you had a biopsy or surgery before starting this study and possible another sample if your disease gets worse during this study will be sent to the biobank. In addition, you will be asked to provide urine samples on the day 1 of treatment cycles 1, 2, and 5, and if your disease gets worse.
2. Your samples will be stored in the biobank. There is no limit on the length of time we will keep your samples and research information. The samples will be kept until they are used for research or destroyed.
3. Researchers can only get samples from the biobank after their research has been approved by experts. Researchers will not be given your name or contact information.
4. Some of your genetic and health information may be placed in central databases for researchers to use. The databases will not include your name or contact information.

What are the risks in this optional sample collection?

- The most common risks related to drawing blood from your arm are brief pain and maybe a bruise.
- Generally, hospitals will keep some of your tissue. This tissue may be used to help treat your cancer in the future. There is a small risk that when this tissue sample is submitted to the biobank for this optional sample collection, your tissue could be used up.
- Your medical and genetic information is unique to you. There is a risk that someone outside of the research study could get access to your study records or trace information in a database back to you. They could use that information in a way that could harm you. Researchers believe the chance that someone could access and misuse your information is very small. However, the risk may increase in the future as people find new ways of tracing information.
- In some cases, this information could be used to make it harder for you to get or keep a job and get or keep health insurance.

How will information about me be kept private?

Your privacy is very important to the study researchers and biobank. They will make every effort to protect it. Here are just a few of the steps they will take:

1. They will remove identifiers, such as your initials, from your sample and information. They will replace them with a code number. There will be a master list linking the code numbers to names, but they will keep it separate from the samples and information.
2. Researchers who study your sample and information will not know who you are. They also must agree that they will not try to find out who you are.
3. Your personal information will not be given to anyone unless it is required by law.
4. If research results are published, your name and other personal information will not be used.

What are the benefits to taking part in this optional sample collection?

You will not benefit from taking part.

The researchers, using the samples from you and others, might make discoveries that could help people in the future.

Are there any costs or payments to this optional sample collection?

There are no costs to you or your insurance. You will not be paid for taking part in this study. The research may lead to new tests, drugs, or other products for sale. If it does, you will not get any payment.

What if I change my mind about this optional sample collection?

If you decide you no longer want your samples to be used, you can call the study doctor, _____, *(insert name of study doctor for main trial)* at _____ *(insert telephone number of study doctor for main trial)*, who will let the biobank know. Then, any sample that remains in the biobank will be destroyed or returned to your study doctor. This will not apply to any samples or related health information that have already been given to or used by researchers.

What if I have questions about this optional sample collection?

If you have questions about the use of your samples for research, contact the study doctor, _____, *(insert name of study doctor for main trial)*, at _____ *(insert telephone number of study doctor for main trial)*.

Please circle your answer below to show if you would or would not like to take part in each optional study:

Samples for known future studies:

1. I agree that my samples and related health information may be used for the laboratory studies described above.

YES

NO

Samples for unknown future studies:

I agree that my left-over samples and related health information may be kept in a biobank for use in future health research.

YES

NO

Contact for Future Research

2. I agree that my study doctor, or someone on the study team, may contact me or my doctor to see if I wish to participate in other research in the future.

YES

NO

This is the end of the section about optional studies.

My signature agreeing to take part in the study

I have read this consent form or had it read to me. I have discussed it with the study doctor and my questions have been answered. I will be given a signed and dated copy of this form. I agree to take part in the main study. I also agree to take part in any additional studies where I circled “yes”.

Participant’s signature

Date of signature

Signature of person(s) conducting the informed consent discussion

Date of signature